Pharmatest's in vitro cancer cell assays include assays of cell viability and cell invasion. Cell viability is measured using CellTiter-Glo® luminescent cell viability assay (CTG), a homogeneous method for determining the number of viable cells in culture. The cell viability assays are rapid and reliable screening tools for cancer drug discovery, and they are available in automated high-throughput screening (HTS) platforms.
Cancer cell invasion is measured using a commercially available BD BioCoatTM FluoroBlokTMInvasion System, where the cancer cells are grown on a basement membrane-like MatrigelTM coated filter chamber. The capacity of the cells to migrate through the MatrigelTM layer is determined and cell invasion is quantitated by post-labelling the cancer cells with a fluorescent dye. The subsequent fluorescence of the invaded cells is then measured as endpoint data.
The following table lists cancer cell lines that are available in Pharmatest for both in vitro assays and subsequent orthotopic and/or metastasis models, allowing to test efficacy of promising compounds in clinically relevant in vivo models using the cell lines that they inhibited in vitro. A list of other cancer cell lines that are also available for in vitro studies, but without a validated orthotopic or metastasis model, can be found here.
Cell line | Cancer | Species | Viability | Invasion |
MDA-MB-231 | Breast cancer | Human | X | X |
MCF-7 | Breast cancer | Human | X | |
4T1 | Breast cancer | Mouse | X | |
PC-3 | Prostate cancer |
Human | X | X |
LNCaP | Prostate cancer | Human | X | |
VCaP | Prostate cancer | Human | X | |
5TGM1 | Multiple myeloma |
Mouse | X | |
BxPC-3 | Pancreatic cancer |
Human | X |